

Company Registration Number - 8013670

The Charity Registration Number is :- 1147506

Ocular Melanoma UK

Report and Accounts

31 March 2024

Ocular Melanoma UK

Report and accounts for the year ended 31 March 2024

Contents

	Page
Charity information	1
Trustees' Annual Report	1
Statement of directors' responsibilities	11
Independent Accountant's Report	13
<i>Funds Statements:-</i>	
Statement of Financial Activities	15
Statement of Financial Activities - Prior Year statement	16
Movements in funds	17
Income and Expenditure account	18
Balance sheet	19
Notes to the accounts	20

Ocular Melanoma UK

Company Registration Number - 8013670

Trustees' Annual Report for the year ended 31 March 2024

The Trustees present their Report and Accounts for the year ended 31 March 2024, which also comprises the Directors' Report required by the Companies Act 2006.

Reference and administrative details

The charity name.

The legal name of the charity is:- Ocular Melanoma UK.

The charity is also known by its operating name, Ocular Melanoma UK.

The charity's areas operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1147506.

The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts .

The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 26 March 2012

Updated Articles of Association and Special Resolution are dated 20th August 2024

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:-

139 Langley Road

Slough, Berkshire

UK, SL3 7DZ

Telephone 01753 357771

Email Address info@omuk.org

Web Address www.omuk.org

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

Ocular Melanoma UK

Company Registration Number - 8013670

Trustees' Annual Report for the year ended 31 March 2024

The Trustees in office on the date the report was approved were:-

Mr Neil Pearce

Mrs Alison Benjamin

Mrs Joanne Morgan - Chair

Mr Gianfranco De Franco

Mr Colin White

Mrs Charlotte Edwards - Treasurer

The following persons served as Trustees during the year ended 31 March 2024 :-

The trustees who served as a trustee in the reporting period, and, if applicable, their dates of appointment or resignation during the year were:-.

Name	Appointed	Resigned/Retired
Mr Neil Pearce		
Mrs Alison Benjamin		
Mrs Joanne Morgan - Chair		
Mr Gianfranco De Franco		
Mr Colin White		
Mrs Charlotte Edwards - Treasurer		
All the trustees are also members of the charity.		

Ocular Melanoma UK

Company Registration Number - 8013670

Trustees' Annual Report for the year ended 31 March 2024

Objects and activities of the charity

The purposes of the charity.

Ocular Melanoma UK is the only UK charity solely dedicated to supporting people affected by ocular melanoma. We have been helping people since 2011 with this rare cancer so they could talk to others about their cancer diagnosis and adjust to life if they experience vision loss.

We are determined to drive improvements so people can live well with ocular melanoma. This can be a devastating cancer so we are working to ensure people have access to effective treatments and that clear pathways are in place, all while striving to provide specialist support to people who need it.

What is ocular melanoma?

Ocular melanoma is a cancer of the eye.

- We know approximately 750 people in the UK will hear they have ocular melanoma each year and those people are likely to need support.
- We know we have hundreds of people in the UK living with ocular melanoma who may need support adjusting to life after their diagnosis.
- We also know one in every two people will hear they need further treatment if the cancer spreads
- We know that no one should face this terrifying time alone.

Ocular melanoma includes two cancers, uveal and conjunctival melanoma. Uveal melanoma includes the iris, choroid or ciliary body. Both types of ocular melanoma can metastasise (spread) to other organs, with the liver typically involved in 90% of uveal melanoma cases.

If ocular melanoma spreads to another organ, it is currently incurable. Some treatments extend life expectancy and improve the quality of life for some patients, but patients can face difficulties accessing these treatments.

Ocular melanoma is usually discovered during a routine eye examination, or when the patient experiences symptoms and goes to their GP or optometrist. If the optometrist or GP suspects cancer, they should urgently refer the patient to their local ophthalmology department, should they agree with the concern, they will refer to one of four specialist centres: Glasgow, Liverpool, Sheffield or London.

Why is Ocular Melanoma UK needed?

People with ocular melanoma can feel very alone. The condition is so rare and the prognosis often so overwhelming, that patients frequently report feeling isolated. Ocular Melanoma UK came about to provide both support and a voice for those with this rare cancer. We bring people together across the country and provide UK-specific information.

Ocular Melanoma patients are often excluded from skin melanoma trials, so research is limited. Treatments are progressing, but many people face barriers to receiving treatments

Ocular Melanoma UK is raising the disease profile within the medical community and decision-makers. We work to improve patients' access to effective treatments, and eventually financially support research.

Ocular Melanoma UK

Company Registration Number - 8013670

Trustees' Annual Report for the year ended 31 March 2024

Our aims and objectives

Our Vision is a world where people with ocular melanoma can live, and live well.

Our Mission is to advocate for change by uniting people against ocular melanoma cancers so that every person receives the treatment, information and support they need.

Ocular Melanoma UK's charitable objectives are:

1. To primarily promote and protect the physical and mental health of people with ocular melanoma and their families in the United Kingdom through support, information, education and practical advice.
2. To support research into ocular melanoma and to publish the useful results.

The main activities undertaken during the year to further the charity's purpose for the public benefit.

Ocular Melanoma UK provides members and others with current information and non-clinical advice and support through various channels.

People tell us they wish they learnt about us when they were first diagnosed as they appreciate the information and support we provide. This means a great deal to them, so we have planned several projects to increase our reach so that once someone is diagnosed, they learn about Ocular Melanoma UK, the services we provide, and that we can encourage treatment pathways to be developed to ease the pressures people face.

During the year, we supported our community by offering the following services:

To Improve Support

Emotional & Practical Support

We recruited a dedicated Helpline Advisor who is supporting more people through our helpline and manages our online community support groups which are open to anyone affected by this cancer. These weekly meetings provide a safe place for people to give and receive support with any difficulties they face.

Psychological Support

Continued to provide members with timely & funded professional support with a specialist Health Psychologist to ease the impact this diagnosis can have. This allows patients and loved ones throughout the UK to access up to six funded sessions.

Health Information

We gained pif-tick accreditation so our health information is easily recognised as a trusted source of information and reviewed by clinicians to ensure it is clinically accurate and written in conjunction with patients so it contains information that they would find useful.

Our first booklet is now available on our website for people with metastatic disease and we will be launching the next booklets about the condition and receiving treatment for the primary tumour shortly.

Community Support

As mentioned above, we run regular online sessions for people to come together to remove isolation and facilitate peer-to-peer support. We have also increased the number of local ambassadors so that people can meet other members throughout the UK in person.

Ocular Melanoma UK

Company Registration Number - 8013670

Trustees' Annual Report for the year ended 31 March 2024

To Build Knowledge

Conference

We held a two-day conference which was very well attended by patients and family members. We had a record number of people who hadn't attended a conference before and for some, it was the first time they met others with the same condition, which is a huge help in itself.

We also had some of the leading experts in their field share their knowledge with us. Every year, we ensure these talks are recorded and available after the event so the latest knowledge is easily shared.

Website

We have launched a new website which now meets accessibility criteria, www.omuk.org. We have launched this in phases so that all cancer-related information adheres to pif-tick quality health information standards and have now begun work on building a resource for people to find details of the clinical trials they could be eligible for and we are building an area for clinicians to find information easily.

Ocular Melanoma October

In October 2024, we launched Ocular Melanoma October, a month-long campaign to raise awareness about ocular melanoma and provide support to those affected by this rare cancer. The campaign featured educational content, community events, and culminated in the first Ocular Melanoma Day on 10 October, marking the charity's 15th anniversary. It resulted in a fourfold increase in our social media reach and connected individuals nationwide through in-person meetings. This success laid the foundation for an expanded awareness initiative next year, with funding already secured. Ocular Melanoma October will now become an annual tradition to amplify our impact and ensure no one faces ocular melanoma alone.

Bulletins

We produce a regular bulletin for our members giving updates on our work, how to access the services we provide, and importantly, information on how people can share their experience with us or decision-makers to drive improvements.

Advocacy

This has been a large part of our work as NICE felt a new drug should not be made available. We successfully appealed this decision and it was recently announced that this new treatment, Tebentafusp will be available to people on the NHS. We continued to involve our community at every stage by running focus groups and we worked closely with two patients so they could attend the meetings and explain to the committee what it was like to live with this condition. One of our members shared her experience of taking the new drug through the clinical trial and this insight was incredibly useful for the committee.

Rare Community

Ocular Melanoma UK is a member of Cancer52 and Genetic Alliance and regularly attends NHS England Cancer Charity meetings so key messages can be communicated to our community, but also allows us to communicate the needs of people affected by ocular melanoma to decision-makers. Our CEO also works with Melanoma Patient Network for Europe and useMYdata and sits on various projects to improve the lives of people with this cancer.

Ocular Melanoma UK

Company Registration Number - 8013670

Trustees' Annual Report for the year ended 31 March 2024

To Drive Research

Clinical Advisory Panel

We have continued to work with our clinical advisory panel to gain their thoughts on how to resolve areas that are important to patients and to ensure the information we provide is clinically accurate.

Research applications

We supported several research applications that we felt would benefit people and met with organisations interested in learning about the impact of this cancer. At times it was appropriate for us to lead those conversations, but where companies were interested in talking to patients directly, we reviewed the questions that would be asked and offered our support to the people involved.

Data

We have worked to improve the data routinely available to researchers and bodies such as NICE & SMC and will continue to push for better data collection and sharing of data so that the needs of patients are clearly understood.

Access to Medicines

We continued to build relationships with pharmaceutical companies who have an interest in this cancer to increase the number of trials available to people and to increase the possibility of effective treatments being made available to people.

We successfully appealed a decision by NICE to not recommend a new drug and are very pleased that patients can now receive this treatment on the NHS.

We continue to encourage NHS England to allow chemosat to be funded and have supported patients while they appeal to private medical companies to have their decisions overturned.

Patient Need

We have expanded our reach so that more organisations understand that the needs of rare cancer patients are not being met with the current focus on improving mortality in the UK. We do this through working with organisations that share common goals and enable us to have a voice at a national level.

All this was achieved with the support of our donors and everyone who fundraised for us. We are incredibly grateful to everyone for their efforts over this challenging year as it enabled us to continue our work and support people through some very difficult times.

The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity.

Ocular Melanoma UK

Company Registration Number - 8013670

Trustees' Annual Report for the year ended 31 March 2024

Structure, governance and management of the charity

The methods used to recruit and appoint new charity trustees.

Governing Document

The organisation is a charitable company limited by guarantee, incorporated on 30 March 2012 and registered as a charity on 30 May 2012. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.

Management Committee

Our CEO was a trustee of the charity up until 31/03/23 and this was approved by the Charity Commission. All other Trustees gave and continue to give their time voluntarily and received no benefits from the charity. Any expenses reclaimed from the charity are set out in note 8 to the accounts. Trustees serve for up to three years and may be re-elected at the Annual General Meeting. The Board of Directors, together with the CEO, acts as the Management Committee.

Trustee Induction

Trustees have been appointed based on their ability to lead the Charity on behalf of the membership, and are a mix of people who either have existing knowledge of Ocular Melanoma, either as medical professional or patient or family of patient, or who bring necessary professional expertise.

Trustees are also directors registered with Companies House.

A comprehensive trustee information pack is supplied to each trustee, together with cross-references to the guidance published by the Charity Commission (for trustees) and by Companies House (for directors).

Organisational Structure

The Management Committee is responsible for the strategic direction and policy of the charity. The CEO has delegated responsibility from the Board for the overall operation of the charity.

Bankers

CAF Bank - Kings Hill, West Malling, Kent, ME19 4JQ

National Westminster Bank Plc, Earls Court, Enfield CSC, Lee House,
Bairs Road, Middlesex, EN1 1FD

Shawbrook Bank, Lutea House, Warley Hill Business Park, The Drive, Great
Warley, Brentwood, Essex CM13 3BE

Ocular Melanoma UK

Company Registration Number - 8013670

Trustees' Annual Report for the year ended 31 March 2024

Financial review

The charity's financial position at the end of the year ended 31 March 2024

The financial position of the charity at 31 March 2024 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2024	2023
	£	£
Net income	(688)	(11,805)
Unrestricted Revenue Funds available for the general purposes of the charity	41,408	54,910
Restricted Revenue Funds	36,607	23,793
Total Restricted Funds	36,607	23,793
Total Funds	78,015	78,703

Financial review of the position at the reporting date, 31 March 2024

The trustees consider the financial performance by the charity during the year to have been satisfactory.

Ocular Melanoma UK

Company Registration Number - 8013670

Trustees' Annual Report for the year ended 31 March 2024

Policies on reserves

This reserves policy aims to establish guidelines for the appropriate level of reserves that Ocular Melanoma UK should maintain. The reserves policy will help ensure that Ocular Melanoma UK has the financial resources to fulfil its mission and objectives, respond to emergencies, and manage risks. The reserves policy will also provide transparency and accountability to Ocular Melanoma UK's stakeholders, including donors, volunteers, staff, and beneficiaries.

Nature of reserves:

For the purposes of this policy, reserves are defined as funds that are held in excess of the immediate needs of Ocular Melanoma UK. Reserves include both unrestricted and restricted funds.

Reserves Guidelines:

1. **Target Reserves:** Ocular Melanoma UK should maintain a target reserve level equivalent to at least six months of operating expenses. The target reserves will be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.
2. **Minimum Reserves:** Ocular Melanoma UK should maintain a minimum level of reserves that is equivalent to three months of operating expenses. The minimum reserves will be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.
3. **Use of Reserves:** Reserves should only be used for specific purposes, such as emergencies, unexpected expenses, or to support new initiatives. Reserves should not be used to cover ongoing operational deficits or to fund programs that are not sustainable.
4. **Investment of Reserves:** Reserves should be invested in a prudent manner that balances safety, liquidity, and yield. The investment strategy should be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.
5. **Reporting on Reserves:** Ocular Melanoma UK will report annually on the status of its reserves in its financial statements. This reserves policy ensures that Ocular Melanoma UK has the financial resources to fulfil its mission and objectives, respond to emergencies, and manage risks.

The policy provides guidelines for the appropriate level of reserves, the use and investment of reserves, and reporting on reserves. The policy will be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.

Availability and adequacy of assets of each of the funds

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

Ocular Melanoma UK

Company Registration Number - 8013670

Trustees' Annual Report for the year ended 31 March 2024

Plans For the Future

Summary of plans for the future and the trustees' perspective of the future direction of the charity.

We strive to improve the care, treatment and support patients receive.

We will continue our work so that once someone is diagnosed, they learn about Ocular Melanoma UK & the services we provide, and that treatment pathways are developed to ease the pressures that we know people face.

We identified several ways to reduce these pressures, building our small charity so it can help people and their families through these difficult times.

In addition to the services outlined earlier in this report, we will continue to focus efforts to

Reduce delays in accessing treatment for metastatic disease and
Increase our services that reduce isolation and distress.

We will do this by

- Ensuring people can easily find clinical trials known to us as these will be shared on the new website. This remains incredibly important as there is no other resource that shows all the trials that could be useful to our patients.
- Representing our community at NICE, SMC & NHS reviews so that treatments that can help our community become available to the patients that need them.
- Continuing the development of a suite of literature with information that our community feels is important, and ensuring we continue to meet pif-tick standards so we are a trusted source of health information.
- Raising the profile of this disease so that people are diagnosed sooner and this cancer has a lesser impact on them.
- Hosting a conference for people to learn more about clinical developments in this area, information on how people can live well with this cancer, and importantly to bring people together for peer-to-peer support.
- Increasing the number of volunteers, including our local ambassadors so local meetings can take place around the country.
- Using all the resources we have available so that we are not held back because of financial constraints. Our support is important to people, so we will ensure our small team is correctly placed to achieve the plans outlined in our 3-year strategy.

Everything Ocular Melanoma UK has achieved has been through sheer dedication and a passion to make a real change in the lives of those affected by this dreadful cancer.

We will continue until we have a world where people with ocular melanoma can live, and live well.

Details of The Independent Examiner

Tracey Pritchard BA FCA
Member of Chartered Accountant
255 Poulton Road
Wallasey
Merseyside
CH44 4BT

Ocular Melanoma UK

Company Registration Number - 8013670

Trustees' Annual Report for the year ended 31 March 2024

Statement of the Directors Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Ocular Melanoma UK

Company Registration Number - 8013670

Trustees' Annual Report for the year ended 31 March 2024


Method of preparation of accounts - Small company provisions

The financial statements are set out on pages 15 to 34.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 17 December 2024.



MRS C EDWARDS
Director and Trustee

Ocular Melanoma UK

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2024

I report to the Trustees on my examination of the financial statements of the charitable company on pages 15 to 34 for the year ended 31 March 2024 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), and under the historical cost convention and the accounting policies set out on page 20.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 11, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- a) examine the financial statements of the charity under Section 145 of the Act;
- b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner's Statement and scope of work undertaken

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Ocular Melanoma UK

Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;


the financial statements do not accord with those records; or

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;

have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-



Tracey Pritchard BA FCA - Independent Examiner

Chartered Accountant

255 Poulton Road
Wallasey
Merseyside
CH44 4BT

This report was signed on 17/12/2024

Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2024

Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2024, as required by the Companies Act 2006)

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024 £	2024 £	2024 £	2023 £
Income & Endowments from:					
Donations & Legacies	A1	42,133	61,000	103,133	100,037
Charitable activities	A2	325	-	325	141
Other trading activities	A3	45,317	-	45,317	28,754
Investments	A4	520	-	520	238
Total income	A	88,295	61,000	149,295	129,170
Expenditure on:					
Raising funds	B1	2,972	-	2,972	1,144
Charitable activities	B2	90,800	56,211	147,011	139,831
Total expenditure	B	93,772	56,211	149,983	140,975
Net income for the year		(5,477)	4,789	(688)	(11,805)
Transfers between funds	C	(8,025)	8,025	-	-
Net income after transfers	A-B-C	(13,502)	12,814	(688)	(11,805)
Net movement in funds		(13,502)	12,814	(688)	(11,805)
Reconciliation of funds:-					
Total funds brought forward		54,910	23,793	78,703	90,508
Total funds carried forward		41,408	36,607	78,015	78,703

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All activities derive from continuing operations

The notes attached on pages 20 to 34 form an integral part of these accounts.

Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2024

Ocular Melanoma UK - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Income & Endowments from:				
Donations & Legacies	A1	34,837	65,200	100,037
Charitable activities	A2	141	-	141
Other trading activities	A3	28,754	-	28,754
Investments	A4	238	-	238
Total income	A	63,970	65,200	129,170
Expenditure on:				
Raising funds	B1	1,144	-	1,144
Charitable activities	B2	98,424	41,407	139,831
Total expenditure	B	99,568	41,407	140,975
Net gains on investments	B4	-	-	-
Net income for the year		(35,598)	23,793	(11,805)
Transfers between funds	C			-
Net income after transfers		(35,598)	23,793	(11,805)
Net movement in funds		(35,598)	23,793	(11,805)
Reconciliation of funds:-				
Total funds brought forward		90,508	-	90,508
Total funds carried forward		54,910	23,793	78,703

Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2024

Ocular Melanoma UK - Resources applied in the year ended 31 March 2024 towards fixed assets for Charity use:-

	2024 £	2023 £
Funds generated in the year as detailed in the SOFA	(688)	(11,805)
Resources applied on functional fixed assets	-	(427)
Other applications of funds	-	-
Net resources available to fund charitable activities	(688)	(12,232)

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 20 to 34 form an integral part of these accounts.

Movements in revenue and capital funds for the year ended 31 March 2024

Revenue accumulated funds

	Unrestricted Funds 2024 £	Restricted Funds 2024 £	Total Funds 2024 £	Last year Total Funds 2023 £
Accumulated funds brought forward	54,910	23,793	78,703	90,508
Recognised gains and losses before transfers	(5,477)	4,789	(688)	(11,805)
	49,433	28,582	78,015	78,703
(From)/To unrestricted revenue funds	(8,025)	8,025	-	-
Closing revenue funds	41,408	36,607	78,015	78,703

Summary of funds

	Unrestricted and Designated funds 2024 £	Restricted Funds 2024 £	Total Funds 2024 £	Last Year Total Funds 2023 £
Revenue accumulated funds	41,408	36,607	78,015	78,703

The notes attached on pages 20 to 34 form an integral part of these accounts.

Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2024

Ocular Melanoma UK Income and Expenditure Account for the year ended 31 March 2024 as required by the Companies Act 2006

	2024 £	2023 £
Income		
Income from operations	148,775	128,932
Investment income		
Interest receivable	520	238
Gross income in the year before exceptional items	149,295	129,170
Gross income in the year including exceptional items	149,295	129,170
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	145,598	108,514
Depreciation and amortisation	243	529
Fundraising costs	2,972	1,144
Governance costs	1,170	30,788
Total expenditure in the year	149,983	140,975
Net income before tax in the financial year	(688)	(11,805)
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	(688)	(11,805)
Retained surplus for the financial year	(688)	(11,805)

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 20 to 34 form an integral part of these accounts.

Ocular Melanoma UK - Balance Sheet as at 31 March 2024

		SORP		2024	2023
	Note	Ref		£	£
Fixed assets		A			
Tangible assets	10	A2		238	481
Current assets		B			
Stocks		B1	2,108		2,108
Debtors	12	B2	-		-
Cash at bank and in hand		B4	77,273		77,236
Total current assets			79,381		79,344
Creditors: amounts falling due within one year	13	C1	(1,604)	(1,122)	
Net current assets				77,777	78,222
The total net assets of the charity				<u>78,015</u>	<u>78,703</u>

The total net assets of the charity are funded by the funds of the charity, as follows:-

Restricted funds					
Restricted Revenue Funds	17	D2	36,607	23,793	
			36,607		23,793
Unrestricted Funds					
Unrestricted Revenue Funds	17	D3	41,408	54,910	
			41,408		54,910
Total charity funds			<u>78,015</u>		<u>78,703</u>

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 14.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.



MRS C EDWARDS

Trustee

Approved by the board of trustees on 17 December 2024

The notes attached on pages 20 to 34 form an integral part of these accounts.

Ocular Melanoma UK

Notes to the Accounts for the year ended 31 March 2024

1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Risks and future assumptions

The charity is a public benefit entity.

The Management Committee has reviewed the major risks to which the charity has been exposed. Where appropriate, systems or procedures have been established to mitigate the risks the charity faces.

Our Regional Representatives are each issued with the Ocular Melanoma UK Representative Handbook and are invited to attend a training session.

Financial control risks are minimised by the implementation of procedures for authorisation of all transactions.

Accounting for deferred income and income received in advance

Where terms and conditions relating to income have not been met or uncertainty exists as to whether the charity can meet any terms or conditions otherwise within its control, income is not recognised but is deferred as a liability until it is probable that the terms or conditions imposed can be met.

Any grant that is subject to performance-related conditions received in advance of delivering the goods and services required by that condition, or is subject to unmet conditions wholly outside the control of the recipient charity, is accounted for as a liability and shown on the balance sheet as deferred income. Deferred income is released to income in the reporting period in which the performance-related or other conditions that limit recognition are met.

When income from a grant or donation has not been recognised due to the conditions applying to the gift not being wholly within the control of the recipient charity, it is disclosed as a contingent asset if receipt of the grant or donation is probable once those conditions are met.

Where time related conditions are imposed or implied by a funder, then the income is apportioned to the time periods concerned, and, where applicable, is accounted for as a liability and shown on the balance sheet as deferred income. When grants are received in advance of the expenditure on the activity funded by them, but there are no specific time related conditions, then the income is not deferred.

Any condition that allows for the recovery by the donor of any unexpended part of a grant does not prevent recognition of the income concerned, but a liability to any repayment is recognised when repayment becomes probable.

Ocular Melanoma UK

Notes to the Accounts for the year ended 31 March 2024

Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock. When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in 'legacies and donations'. Goods donated for resale are included in 'Income from other trading activities'.

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received, (provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

Policies relating to assets, liabilities and provisions and other matters.

Tangible fixed assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery	over 3 years
---------------------	--------------

A regular annual review of the likelihood of asset impairment is undertaken.

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

There are no endowment funds.

Ocular Melanoma UK

Notes to the Accounts for the year ended 31 March 2024

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4 Significance of financial instruments to the charity's position

There are no significant implications of such matters

5 Net surplus before tax in the financial year

	2024 £	2023 £
The net surplus before tax in the financial year is stated after charging:-		
Depreciation of owned fixed assets	243	529
Trustees' Remuneration as detailed in note 8	-	29,708
Pension costs	3,886	4,195

6 Staff costs and emoluments

<i>Salary costs</i>	2024 £	2023 £
Gross Salaries excluding trustees and key management personnel	97,851	66,373
Employer's operating costs of defined contribution pension schemes	3,886	4,195
Trustees' Remuneration as detailed in note 8	-	29,708
Total salaries, wages and related costs	101,737	100,276

The average number of full time staff employed in the year was	1	1
The estimated full time equivalent number of all staff employed in the year was	3	3

The estimated equivalent number of full time staff deployed in different activities in the year was:-

Engaged on charitable activities	3	3
The estimated full time equivalent number of all staff employed as above	3	3

The details of remuneration paid to trustees is shown in note 8

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

7 Defined contribution pension schemes

Any liabilities and assets associated with the scheme are shown under debtors and creditors.

Ocular Melanoma UK

Notes to the Accounts for the year ended 31 March 2024

8 Remuneration and payments to Trustees and persons connected with them

	2024 £	2023 £
<i>Remuneration payable to trustees or connected persons</i>		
Trustee 1	-	28,293
Total remuneration	-	29,708

More detailed information in the Management Committee section on page 7.

9 Trustees' expenses

No trustee expenses were incurred, either in the current or prior year.

10 Tangible fixed assets

<i>Current Year</i>	Land and Buildings £	Plant & Machinery £	Motor Vehicles £	Total £
Cost				
At 1 April 2023	-	3,552	-	3,552
Additions	-	-	-	-
At 31 March 2024	-	3,552	-	3,552
Depreciation				
At 1 April 2023	-	3,071	-	3,071
Charge for the year	-	243	-	243
At 31 March 2024	-	3,314	-	3,314
Net book value				
At 31 March 2024	-	238	-	238
At 31 March 2023	-	481	-	481
<i>Prior Year</i>				
Cost				
01 April 2022	-	3,125	-	3,125
Additions	-	427	-	427
01 April 2023	-	3,552	-	3,552
Depreciation				
01 April 2022	-	2,542	-	2,542
Charge for the year	-	529	-	529
01 April 2023	-	3,071	-	3,071
Net book value				
01 April 2023	-	481	-	481
01 April 2022	-	583	-	583

Ocular Melanoma UK

Notes to the Accounts for the year ended 31 March 2024

11 Stocks & Work in Progress	2024	2023
	£	£
Stocks before write downs	2,108	2,108
	<u>2,108</u>	<u>2,108</u>
12 Debtors	2024	2023
	£	£
Prepayments and accrued income	-	-
13 Creditors: amounts falling due within one year	2024	2023
	£	£
Trade creditors	644	162
Accruals	960	960
	<u>1,604</u>	<u>1,122</u>
14 Income and Expenditure account summary	2024	2023
	£	£
At 1 April 2023	78,703	90,508
Surplus after tax for the year	(688)	(11,805)
At 31 March 2024	<u>78,015</u>	<u>78,703</u>

15 No related party transactions

No trustee or other person related to the charity had any personal interest in any contract or transaction entered into by the charity during the year.

16 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2024	Unrestricted funds	Designated funds	Restricted funds	Total Funds
	£	£	£	£
Tangible Fixed Assets	238	-	-	238
Current Assets	42,774	-	36,607	79,381
Current Liabilities	(1,604)	-	-	(1,604)
	<u>41,408</u>	<u>-</u>	<u>36,607</u>	<u>78,015</u>
At 1 April 2023	Unrestricted funds	Designated funds	Restricted funds	Total Funds
	£	£	£	£
Tangible Fixed Assets	481	-	-	481
Current Assets	55,551	-	23,793	79,344
Current Liabilities	(1,122)	-	-	(1,122)
	<u>54,910</u>	<u>-</u>	<u>23,793</u>	<u>78,703</u>

Ocular Melanoma UK

Notes to the Accounts for the year ended 31 March 2024

17 Change in total funds over the year as shown in Note 16 , analysed by individual funds

	Funds brought forward from 2023	Movement in funds in 2024	Transfers between funds in 2024	Funds carried forward to 2025
	£	See Note 18 £	£	£
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	54,910	(5,477)	(8,025)	41,408
Total unrestricted and designated funds	54,910	(5,477)	(8,025)	41,408
Restricted funds:-				
Patient Education & Events(Annual Conference)	-	7,167	-	7,167
Patient folder	3,675	-	-	3,675
Patient Information to PiTick standard	9,766	(7,883)	-	1,883
Resources HCP	-	2,333	-	2,333
Trial Database	-	2,333	-	2,333
Helpline Advisor Role and Support	7,707	(2,296)	5,133	10,544
Psychological Support	2,645	(698)	2,892	4,839
Educational Event	-	3,833	-	3,833
Total restricted funds	23,793	4,789	8,025	36,607
Total charity funds	78,703	(688)	-	78,015

18 Analysis of movements in funds over the year as shown in Note 17

	Income	Expenditure	Other Gains & Losses	Movement in funds
	2024 £	2024 £	2024 £	2024 £
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	88,295	(93,772)	-	(5,477)
Restricted funds:-				
Restricted Fixed Asset Funds	-	-	-	-
Restricted Revaluation Reserve	-	-	-	-
Conference and educational events	21,000	(13,833)	-	7,167
Patient folder	-	-	-	-
Patient Information to PiTick standard	7,833	(15,716)	-	(7,883)
Resources HCP	2,333	-	-	2,333
Trial Database	2,333	-	-	2,333
Helpline Advisor Role and Support	15,333	(17,629)	-	(2,296)
Psychological Support	8,335	(9,033)	-	(698)
Educational Event	3,833	-	-	3,833
	149,295	(149,983)	-	(688)

Ocular Melanoma UK

Notes to the Accounts for the year ended 31 March 2024

19 The purposes for which the funds as

Unrestricted and designated funds:-

Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and, subject to charity legislation, are free from all restrictions on their use.

Restricted funds:-

Restricted Revenue Funds:

Restricted funds are funds that donors have given for a particular purpose and/or project as outlined by donors and may include other connected costs. The aim and use of each restricted fund are detailed in the notes of the financial statements.

20 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

This analysis is classsified by conventional nominal descriptions and not by activity.

21 Donations, Grants and Legacies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Small donations individually less than £1000	21,996	-	21,996	19,232
Just Giving - anonymous donors	2,329	-	2,329	-
CLS UK	1,000	-	1,000	-
In Memory	13,786	-	13,786	13,387
Total donations and gifts from individuals	39,111	-	39,111	32,619

Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds	
	2023	2023	2023	
	£	£	£	
Prior year	32,619	-	32,619	

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Legacies receivable				
Late CH	-	-	-	2,218
Total legacies receivable	-	-	-	2,218

Legacies receivable - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2023	2023	2023
	£	£	£
Prior year	2,218	-	2,218

Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Arnold Clark	-	-	-	1,000
Delcath Systems Ltd	-	11,000	11,000	13,100
Immunocore Limited	-	32,000	32,000	41,100
National Lottery	-	-	-	10,000
Vision Foundation	-	9,000	9,000	-
Alan Boswell Charity ALA	3,022	-	3,022	-
Souter Charitable Trust	-	3,000	3,000	-
TriSalus Life Science	-	3,000	3,000	-
Ideya Biosciences	-	3,000	3,000	-
Total private sector revenue grants	3,022	61,000	64,022	65,200

Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2023	2023	2023
	£	£	£
Prior Year	-	65,200	65,200

Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

Total Donations, Grants and Legacies

<i>Current year</i>		Unrestricted Funds	Restricted Funds	Current Year Total Funds	Prior Year Total Funds
		2024	2024	2024	2023
		£	£	£	£
Total Donations, Grants and Legacies	A1	42,133	61,000	103,133	100,037
<i>Prior year</i>		Unrestricted Funds	Restricted Funds	Prior Year Total Funds	
		2023	2023	2023	
		£	£	£	
Total Donations, Grants and Legacies	A1	34,837	65,200	100,037	

22 Income from charitable activities - Trading Activities

<i>Current year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total funds
		2024	2024	2024	2023
		£	£	£	£
Primary purpose and ancillary trading					
Sale of goods and services in accordance with the charity's objects		325	-	325	141
Total Primary purpose and ancillary trading		325	-	325	141
<i>Prior year</i>		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds	
		2023	2023	2023	
		£	£	£	
Primary purpose and ancillary trading					
Sale of goods and services in accordance with the charity's objects		141	-	141	
Total Primary purpose and ancillary trading		141	-	141	

Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

23 Total Income from charitable activities

<i>Current year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Total income from charitable trading	325	-	325	141
Total from charitable activities A2	325	-	325	141

Income from charitable activities - Prior Year analysis

<i>Prior year</i>	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2023	2023	2023
	£	£	£
Total income from charitable trading	141	-	141
Income from funders	-	-	-
	141	-	141

Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

24 Income from other, non charitable, trading activities

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Income from fundraising events	45,317	-	45,317	28,754
Total from other activities	45,317	-	45,317	28,754

Income from other, non charitable, trading activities - Prior Year analysis

	Unrestricted Funds	Restricted Funds	Total Funds
Prior Year	28,754	-	28,754

Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

25 Expenditure on charitable activities - Direct spending

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Gross wages and salaries - charitable activities	66,951	30,900	97,851	66,373
Defined contribution pension costs - charitable activities	3,886	-	3,886	4,195
Travel and Subsistence - Charitable Activities	747	-	747	1,079
Marketing and advertising of charitable services	118	-	118	1,595
Charitable activities costs	1,395	25,311	26,706	21,025
Training costs	-	-	-	-
Total direct spending	73,097	56,211	129,308	94,267
All the expenditure in the prior year was unrestricted.				
<i>Prior Year</i>	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds	
	2023	2023	2023	
	£	£	£	
Gross wages and salaries - charitable activities	42,310	24,063	66,373	
Defined contribution pension costs - charitable activities	4,195	-	4,195	
Travel and Subsistence - Charitable Activities	1,079	-	1,079	
Marketing and advertising of charitable services	1,595	-	1,595	
Charitable activities costs	3,681	17,344	21,025	
Training costs	-	-	-	
Total direct spending	52,860	41,407	94,267	

Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

26 Support costs for charitable activities

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
<i>Employee costs not included in direct costs</i>				
Recruitment expenses	256	-	256	892
<i>Administrative overheads</i>				
Telephone, fax and internet	1,885	-	1,885	954
Stationery and printing	597	-	597	344
Membership subscriptions	2,662	-	2,662	2,262
Software licences and expenses	2,682	-	2,682	4,094
Sundry expenses	-	-	-	-
Insurance	907	-	907	862
<i>Professional fees paid to advisors other than the auditor or examiner</i>				
Accountancy fees other than examination or audit fees	1,772	-	1,772	1,469
Other legal and professional	5,363	-	5,363	3,119
<i>Financial costs</i>				
Bank charges	132	-	132	205
Depreciation & Amortisation in total for the period	243	-	243	529
Support costs before reallocation	16,499	-	16,499	14,730
Total support costs - Current Year	16,499	-	16,499	14,730

The basis of allocation of costs between activities is described under accounting policies
All the expenditure in the prior year was unrestricted.

27 Other Expenditure - Governance costs

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Independent Examiner's fees	1,170	-	1,170	1,080
Trustees' Remuneration as detailed in note 8	-	-	-	29,708
Total Governance costs	1,170	-	1,170	30,788

All the expenditure in the prior year was unrestricted.

Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

28 Total Charitable expenditure

<i>Current Year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024	2024	2024	2023
		£	£	£	£
Total direct spending	B2a	73,097	56,211	129,308	94,267
Total charitable trading costs	B2b	34	-	34	46
Total support costs	B2d	16,499	-	16,499	14,730
Total Governance costs	B2e	1,170	-	1,170	30,788
Total charitable expenditure	B2	90,800	56,211	147,011	139,831
<i>Prior Year</i>		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds	
		2023	2023	2023	
		£	£	£	
Total direct spending	B2a	52,860	41,407	94,267	
Total charitable trading costs	B2b	46	-	46	
Total support costs	B2d	14,730	-	14,730	
Total Governance costs	B2e	30,788	-	30,788	
Total charitable expenditure	B2	98,424	41,407	139,831	

29 Expenditure on raising funds and costs of investment management

<i>Current Year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024	2024	2024	2023
		£	£	£	£
Cost of fundraising activities		2,972	-	2,972	1,144
Total fundraising costs	B1	2,972	-	2,972	1,144

All the expenditure in the prior year was unrestricted.